Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
FibroGen Inc
FGENCurrent price
1.23 USD
-0.03 USD (-2.38%)
Last closed
1.25 USD
Company
www.fibrogen.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
104 449 168 USD
Yield for 12 month
-34.22 %
1Y
3Y
5Y
10Y
15Y
FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Address: 409 Illinois Street, San Francisco, CA, United States, 94158
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1.75 USDP/E ratio
–Dividend Yield
–Current Year
+147 752 000 USD
Last Year
+140 734 000 USD
Current Quarter
+55 902 000 USD
Last Quarter
+27 138 000 USD
Current Year
+128 904 000 USD
Last Year
+120 454 000 USD
Current Quarter
+30 149 000 USD
Last Quarter
+21 731 000 USD
Key Figures FGEN
1 year
3 years
5 years
10 years
EBITDA
-241 032 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-34.39 %
PEG Ratio
–
Return On Equity TTM
-1015.79 %
Wall Street Target Price
1.75 USD
Revenue TTM
167 492 992 USD
Book Value
-2.29 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
54.6 %
Dividend Yield
–
Gross Profit TTM
-159 212 000 USD
Earnings per share
-2.44 USD
Diluted Eps TTM
-2.44 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
53.6 %
Profit Margin
-143.56 %
Dividend Analytics FGEN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History FGEN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation FGEN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
61.3497
Enterprise Value Revenue
0.307
Price Sales TTM
0.869
Enterprise Value EBITDA
-0.1735
Price Book MRQ
53.8258
Financials FGEN
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators FGEN
For 52 weeks
0.33 USD
2.93 USD
50 Day MA
1.08 USD
Shares Short Prior Month
8 088 406
200 Day MA
1.19 USD
Short Ratio
2.73
Shares Short
7 319 899
Short Percent
8.68 %
BeatStart